RANI News & Events

Rani Therapeutics (RANI) announced the appointment of Nicholas Maestas as CFO, effective immediately. He succeeds Svai Sanford, who announced his departure in May to pursue another professional opportunity. He joins the company from Tempest Therapeutics (TPST), where he served as CFO and head of corporate strategy.

Rani announced that Svai Sanford, CFO, has decided to pursue another professional opportunity and will transition from his role following the appointment of a successor. Sanford will continue to serve as CFO during a transition period to ensure continuity and support an orderly handover of responsibilities.

Reports Q1 revenue $1.7M, consensus $500,000. "In the first quarter of 2026, we strengthened the strategic and scientific foundation of Rani by welcoming two exceptional industry leaders while continuing to advance our lead metabolic program," said Talat Imran, CEO of Rani Therapeutics. "The appointments of Jesper Hoiland as Head of Strategy and Dr. Sara Kenkare-Mitra as Strategic Advisor bring decades of global experience in drug development, commercialization, and portfolio prioritization, expertise that will be instrumental as we evaluate new opportunities for the RaniPill platform and focus our pipeline on programs with the greatest clinical and commercial potential. Their insights come at an important time, as we continue progressing our ongoing Phase 1 trial of RT-114, our first obesity program in the clinic, an oral GLP-1/GLP-2 dual agonist through our partnership with ProGen. With this strengthened leadership and the continued advancement of RT-114, we believe Rani is well-positioned to execute on our 2026 priorities and continue unlocking the potential of oral biologics for patients."